MedCity News
Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies
Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, "deciphering biology" to find new cancer drugs.
Shares0
Drug discovery startup Engine Biosciences has leveraged its computational technology into potential new drugs for itself and its pharmaceutical partners. Now the company has $43 million in financing to continue that work as it looks ahead to its first clinical trials.
The Series A round of funding announced Wednesday was led by Polaris Partners.